The Harley Academy Award for Injectable Product of the Year

RRS® = Repairs….Refills…Stimulates.


The RRS® line of unique injectable formulations allows aesthetic clinics to offer patients unsurpassed biorevitalisation treatments that are highly effective and safe to use for the face and body.

The complete line of RRS® CE Class III sterile injectable medical products consists of three families with 14 different products in total, allowing each practitioner to find the ideal solution for all patient needs and desires.

All products are designed to fill the dermis, provide ideal ‘hydrobalance’ and ‘biorevitalise’ the skin.

RRS® Unique Formulations - Hyaluronic Acid is presented in a ‘biorevitalisation’ solution comprising amino acids with hydration and antioxidant properties that stabilise the HA. The amino acid solution helps the dermal filling effect of the HA by bringing to the dermis amino acids needed for maintaining the intercellular matrix.

RRS® products are also:
• Tailored by indication, for face and body
• Easy to use ready-made cocktails
• Easy to follow approved protocols
• Rapid treatment response
• Stable and durable results
• Compatible with other products and methods
• Cost effective for patient and clinic


Various dermal filler ingredients have been demonstrated as effective biostimulants, increasing hydration and fibroblast activity. The technique known as meostherapy has been used around the world since it was coined in the 1950s by Dr Michael Pistor. Deglesne PA, Arroyo R, Ranneva E, Deprez P. ‘Clinical, Cosmetic and Investigational Dermatology’, (2016) 23; 9: pp.41-53.
Ingredient choice has been based on ingredients that can improve fibroblast function and activity and improve biosynthesis of the extracellular matrix, increasing hydration. Iorizzo M & De Padova MP et al., ‘Biorejuvenation: theory and practice’, Clinics in Dermatology, 2008, 26, pp.177-181

Organic silicium (SI(OH)4) is essential for wound healing, Seaborn CD & Nielsen FH, ‘Silicon deprivation decreases collagen formation in wounds and bone, and ornithine transaminase enzyme activity in liver’, Biological Trace Element Research, 2002, 89, pp.251-61and has been used in mesotherapy solutions for many years, particularly for its benefits in increasing collagen production. Maya V, 'Mesotherapy’, Indian Journal of Dermatology, Venereology and Leprology, 2007,73, pp.60-62 Various studies have demonstrated the effects of organic silicium, one demonstrating a 2,400% increase in hyaluronan synthase 2 gene expression. Ranneva e, Deglesne PA, Arroyo R, Deprez P. Organic silicium increases the synthesis of hyaluronan synthase 2 gene transcript coding for the enzyme responsible for native hyaluronic acid production. J Clin Exp Dermatol Res 2016, 7:3 (Suppl)

Juvéderm® VOLITE is the newest cosmetic injectable from Allergan and is its first Vycross skin quality treatment. Juvéderm® VOLITE is proven to improve skin smoothness (absence of fine lines), hydration and elasticity1,2 from just one treatment. *The improvements in hydration and patient satisfaction last up to six months.1,2,3 No other product in the skin quality category can claim this with this scientific proof.

The creation of Juvéderm® VOLITE was in response to research showing that skin quality is a growing concern globally for patients. 65% of UK women say the appearance of their skin contributes to their outer beauty, and more women say that the look of their skin impacts their perceived outer beauty more than their body shape (65% vs. 39%).4 Consumers also feel that taking care of skin quality leads to both physical and emotional benefits.

Already winner of the Anti-ageing & Beauty Trophy for Best Skin Enhancement Product (2015/2016) and Aesthetics Award winner for Product Innovation of the Year (2016), Profhilo® should win as it is a safe, highly biocompatible product delivered by a specially developed technique minimizing risks for the patient.

Profhilo is the revolutionary BDDE-free, thermally stabilized hyaluronic acid technology for skin remodeling.

Profhilo is manufactured by IBSA Italia who controls the entire product life cycle from the biofermentation of the HA raw material to the finished product in pre-filled syringes.

IBSA, through its extensive scientific knowledge regarding HA and the aim of obtaining products with fewer side effects, developed Profhilo by means of a new patented technology. NAHYCO™ Hybrid Technology combines innovation and complete safety with the production of stabilized hybrid hyaluronic acid cooperative complexes formed through a patented thermal process. It was possible to combine 32mg of low molecular weight HA (L-HA: 80 - 100 KDa) and 32mg of high molecular weight HA (H-HA: 1100 - 1400 KDa) while maintaining complete manageability. A total concentration of 64mg of hyaluronic acid in a 2ml pre-filled syringe, never before reached precisely because of technological limitations. No chemical cross-linking agents are used and the final product, Profhilo, is pure hyaluronic acid sodium salt.

There are products entering the skin quality category but there is no product on the market like Profhilo - none of them is BDDE free, none of them is based on the Hybrid Technology and none of them has the same or even close concentration of hyaluronic acid. Also, the results are very different.

WHAT’S NEW: The abstract titled Hyaluronan hybrid cooperative complexes (Profhilo) and linear and cross-linked HA based injectable medical devices differently affect in vitro Human Adipose Stem Cell differentiation and viability was presented by Prof. Chiara Schiraldi, accepted by the committee and presented during IMCAS 2017. The study has been submitted for publication in Investigative Dermatology and is under review and the results are extremely promising. Profhilo clearly enhances adipogenic differentiation of stem cells derived from human adipose tissue, and their viability more than linear HA and cross-linked hyaluronan based gels. This means from a clinical point of view that Profhilo treatments in the subdermal fat compartment may improve fat tissue renewal. The in vitro experimental outcomes are to be combined with the results of a simultaneous clinical study already completed and will be published before the end of 2017.

Xela Rederm should win Injectable Product of the year due to its’ versatility and astonishing results when it comes to improving the quality, texture, tone and fine lines of the skin.

Redermalization ™ uses Succinic Acid to stimulate collagen and elastin alongside inhibiting Tyrosinase and chelating copper to reduce pigmentation within skin. It comes across no competitors in the market due to its’ patented ingredient combination of hyaluronic acid and succinic acid. It does however follow a similar application technique to mesotherapy.
Only Hyaluronic acid injected in to the dermis can alter the texture and tone of the skin anything subdermally just hydrates. Unlike Mesotherapy, Redermalization with Xela Rederm takes only 3 treatments and comes packaged in a premixed syringe suitable for all skin types and conditions. The succinic acid is an intracellular metabolite that works on the citric acid cycle in the mitochondria converting glucose the ATP and energising the cells. It is also a catalyst for protein production mainly collagen and elastin however other proteins are produced that are vital for cell health and tissue regeneration.

Xela Rederm has the efficacy and strength to rebuild skin as difficult as the peri-orbital zone. Due to the nature of its molecular composition Xela Rederm can be injected right up to the lash line safely and achieve natural results improving the integrity of the skin for a youthful revitalised eye area. No other product can achieve the same results as Xela Rederm due to the patented combination of Hyaluronic Acid and Succinic Acid causing the skin to produce its own collagen and elastin whilst destroying free radicals in the skin preventing the breakdown of our own collagen and elastin.

The support network behind Xela Rederm has grown over the past 12 months. The training for Xela Rederm has changed towards a more personalised in clinic approach, ensuring practitioners fully understand the benefits of Redermalization ™ and the results that can be achieved using the different methods of application. Our highly skilled workforce is on the road to support practitioners in clinic meanwhile our network of experts are always on hand to see that any queries are dealt with as soon as possible.

Hyalual UK have undergone a complete overhaul in our marketing materials. We collected data and feedback from practitioners on what they thought to be the best in clinic marketing materials and what they would find beneficial. This lead to a new marketing material package which is provided to all clients. The package includes Redermalization ™ procedure guidelines, patient information leaflets, thorough consent forms, treatment records and post procedure leaflets so that our practitioners have everything they need to ensure high patient satisfaction and safety.

Belotero® filler treatments provide subtle and smooth results (Ref 1) respecting the personality and expression of the face. How do they do this? Not all HAs are created equal. Belotero is the only Polydensified HA dermal filler with patented Cohesive Polydenisfied MatrixTM Technology which makes a difference in how Belotero® integrates into the skin (Ref 2,3). Through a unique secondary cross linking process, a polydensified gel is formed (Cohesive Polydensified Matrix®) with high and low density zones which means that Belotero can optimally integrate into the skin filling all interstitial spaces(Ref 2). Monodenisfied HAs are limited in their ability to fully integrate due to particle size. The Belotero optimal tissue integration provides many benefits for aesthetic practitioners and patients with a lower risk of inflammatory reaction (Ref 4), no reported Tyndall effect (Ref 5) and the possibility of a more superficial injection technique than conventional (monodensified) HAs, to deliver harmonious and even results (Ref 1) which are less palpable under the skin (Ref 6). There are four products within the Belotero+ range: Soft, Balance, Intense and Volume which have been rheologically tailored to work in harmony for complete facial enhancement. Belotero Soft and Belotero Balance are administered using the blanching technique. This intradermal injection technique, documented in PRS Journal by Dr Patrick Micheels, is specific to Belotero products due to its structure and high degree of integration into the dermis (Ref 7). Using the blanching technique for highly superficial injection allows practitioners to target fine lines and wrinkles with low volume of product, without any reported tyndall effect (Ref 5), resulting in effectiveness and high patient satisfaction levels (Ref 7). Since its launch in 2015, Belotero+ Volume has been established as a key tool in a practitioner’s armamentarium and is advocated by international Key Opinion Leaders, Dr Kate Goldie and Mr Dalvi Humzah. The reason for such strong advocacy is that, unlike conventional monodensified HA volumising fillers, Belotero+ Volume is indicated for both supraperiostal and subcutaneous injection, can be injected through a 30G needle (Ref 8) and through rheologic tailoring is both mouldable and malleable, thus increasing the versatility of this product with a lasting effect of up to 18 months (Ref 9). Dr Welf Prager has recently published a study demonstrating Belotero+ Volume has a stronger volumising capacity than Juvederm® Voluma at any visit, the difference being significant at month three and substantial for months 12 and 18 (Ref 9). In October 2016, Belotero+ Volume was awarded the trophy for Best Filler of the Year (2016-17) at the AMEC Anti-aging Beauty Trophies and in April 2017, Belotero won THE Aesthetics Industry Awards 2017 as part of the Best Injectables Award. Belotero has been designed to be genuinely different, is the world's only polydensified HA filler and has seen its unique rheological design differences recognised both in controlled clinical studies and through other industry awards.

Radiesse®+ (with Lidocaine) is the newest addition to the Merz Aesthetics Injectable Portfolio and is designed to contour and define (ref 1) fundamental areas that accentuate facial shape such as the jawline and lower face.
As we age, the jaw bone becomes narrower through bony resorption and so the width of the jaw decreases and the angle of the jaw becomes less acute or sharp (ref 2). To combat this lower face ageing process, aesthetic practitioners need a product that has optimal capability to do this. Through favourable rheological properties, Radiesse®+ is ideally suited to create shape and definition and preferred by practitioners, like Dr Kate Goldie, because unlike a HA which is hydrophilic, Radiesse+ will not create "heaviness" in the lower face.
Radiesse+ has high levels of viscosity and elasticity, staying in place where it is injected, with the capacity to sculpt and define to reproduce the effect of a strong bony structure (ref 1). The high elasticity means that the skin will have that firmer, youthful ‘bounce back’ effect, supporting the lift and shape without adding weight (ref 1).
The immediate lifting and filling effect of Radiesse+ is gradually followed by new collagen formation (ref 3). Clinical evidence demonstrates that, following the immediate correction effect, Radiesse+ stimulates Type III collagen (that found in scars) that is converted to Type I (that found in healthy, young tissue) which creates structural support and stability within the skin (ref 3). The distinct mode of action effect also promotes an increased production of elastin. This combined effect of collagen and elastin production contributes towards Radiesse®+ delivering a sustained contouring effect for definition and shape in the lower face (ref 3).
Since its launch in September 2016, Radiesse+ has become recognised and loved for its desirable characteristics; FDA approved4 with 0.3% (ref 5) integral lidocaine, patients can expect a positive treatment experience with enhanced patient comfort (ref 5) when compared with Radiesse non lido (ref 6) and the new 27G Terumo needle reduces injection force by 32% when compared to the standard 27G excel needle6. Radiesse has a long-established safety profile and is one of the most studied dermal fillers, with over 200 journal publications demonstrating efficacy and good tolerability.
Radiesse+, as an extension to the already respected and highly evidenced Radiesse brand, has been a welcome addition for many high profile KOLs such as Mr Dalvi Humzah, Dr Kate Goldie, Helena Collier and Drs Simon and Emma Ravichandran, all of whom choose Radiesse+ and even develop their own techniques.
“I have been using Radiesse for over 10 years and the recent Radiesse+ has added to the versatility of this product. It is the product of choice for the "Hammock-Lift (TM)" and ideal for lower facial definition and contouring.” – Mr Dalvi Humzah. (Reference list can be found at the end of question 6).

Princess® Dermal Fillers are non-surgical treatment created using a revolutionary and patent protected S.M.A.R.T technology (Supreme Monophasic and Reticulated Technology). They are monophasic, complex and viscoelastic which makes the smooth and highly elastic at the same time as well as being are non-toxic, non-irritant, non-sensitising and non-pyrogenic.

The S.M.A.R.T technology delivers increased tissue residence with 95.7% of patients still reporting improvement at day 90 after treatment (KOPERA D., PALATIN M., BARTSCH R., BARTSCH K., O‘ROURKE M., HOLLER S., BAUMGARTNER R. R. & PRINZ M. 2015. An open-label uncontrolled, multicenter study for the evaluation of the efficacy and safety of the dermal filler Princess®® VOLUME in the treatment of nasolabial folds. Biomed Res Int, 2015, 195328).

The S.M.A.R.T process uses BDDE as a reticulating (net like) agent to create a very dense network consisting of long and stable chains of Hyaluronic Acid. Even though Princess® dermal fillers use BDDE they have limited BDDE residuals in the finished product (<2 ppm) which is one the lowest on the market.

The gel is homogenised to make it perfectly smooth which creates a gel with a regular injection force for more control throughout the injection. The gel is supplied in a glass syringe making for an easy and smooth injection as the gel does not adhere to the sides of the syringe. These two factors allow for great patient comfort during the injection as well as reduced physician fatigue.

Following a unique purification process BDDE residuals that didn’t react during the cross-linking process and all other undesired compounds such as proteins and endotoxins are cleaned out to achieve the highest
purity and safety.

During the final stage of the S.M.A.R.T process oxygen is removed from the gel to enhance the stability of the gel once it is filled into the syringe.

The unique fully automated no touch technique during the manufacturing process allows every syringe to be calibrated resulting in uniformity and consistency in the product every time. Each syringe contains 23mg/ml of Hyaluronic Acid with the Princess® Filler and Princess® Volume options being available with our without added Lidocaine.

Princess® Dermal Fillers are non-toxic, non-irritant, non-sensitising and non-pyrogenic.

The Princess® Dermal Filler range consists of three products. Princess®® Filler for universal treatments, Princess® Volume, for deep and volumetric treatments and Princess® Rich for Mesotherapy treatments.